patient and doctor discussing brixadi for Moderate to Severe Opioid Use DisorderLocal Altruix pharmacies will fill prescriptions for extended-release buprenorphine injection for patients with moderate to severe opioid use disorder.

ANNAPOLIS, Md.Aug. 17, 2023 /PRNewswire/ — Altruix, a leading provider of behavioral health pharmacy solutions, announced today that it has been selected as a limited distribution partner by Braeburn Inc. for BRIXADI (buprenorphine) extended-release subcutaneous injection (CIII).

BRIXADI is an extended-release injection approved by the FDA to treat moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a transmucosal buprenorphine- containing product. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support.

“BRIXADI is another unique option to help the physicians we partner with to treat the growing threat of opioid use disorder,” says Eric Elliott, CEO, Altruix. “Patients struggling with opioid use disorder are at risk for potentially serious consequences, including long-term addiction or death. BRIXADI provides a noteworthy advancement in providing another option to treat opioid use disorder.”

Clinical trials demonstrated BRIXADI’s efficacy in reducing opioid use. It offers weekly and monthly dosing options for patients already receiving buprenorphine treatment. It is obtained via a prescription and administered by a healthcare professional in a healthcare setting. Altruix partners with patients and prescribers to break down barriers such as prior authorizations and financial obstacles to help patients access BRIXADI.

Due to the risk of serious harm resulting from accidental intravenous (IV) administration, BRIXADI has a Boxed Warning and will be made available through a restricted distribution program called the BRIXADI Risk Evaluation and Mitigation Strategy (REMS). Altruix is certified in this program and complies with all REMS requirements. Information on the BRIXADI REMS program will be available at

View the full press release on PRNewswire.

New call-to-action